Tazeen Ahmad
Stock Analyst at B of A Securities
(3.36)
# 1,020
Out of 4,996 analysts
212
Total ratings
47.77%
Success rate
3.37%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $453 → $520 | $446.40 | +16.49% | 5 | Sep 17, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $82.70 | +25.76% | 6 | Sep 4, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $227 → $230 | $191.99 | +19.80% | 11 | Sep 2, 2025 | |
| ARGX argenx SE | Maintains: Buy | $880 → $887 | $712.03 | +24.57% | 4 | Sep 2, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Underperform | $17 → $16 | $18.36 | -12.85% | 26 | Aug 21, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $82 → $76 | $58.99 | +28.84% | 19 | Aug 20, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $23 → $27 | $21.05 | +28.27% | 16 | Aug 7, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $126 → $134 | $98.08 | +36.62% | 9 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $23 → $24 | $22.39 | +7.19% | 8 | Jul 16, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Buy | $8 | $3.25 | +146.15% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $99.16 | -4.20% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.63 | +96.59% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.41 | -57.49% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $1 → $0.8 | $0.89 | -9.77% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $13.95 | +93.55% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $8.27 | +238.57% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $68.89 | +1.61% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $8.39 | +376.76% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $142.00 | +26.06% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $12.40 | +77.42% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $5.07 | -40.83% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $8.24 | +82.04% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $8.84 | -77.38% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $29.08 | +161.35% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.37 | +196.74% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.00 | +500.00% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $12.53 | +19.71% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $24.17 | -54.48% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.65 | -45.21% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $1.50 | +300.00% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $11.56 | +29.76% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $52.02 | +15.34% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $2.14 | +647.66% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $14.70 | +192.52% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $202.96 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $9.16 | +3,175.11% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $1.89 | +376.19% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $25.24 | +90.17% | 6 | Oct 10, 2018 |
Alnylam Pharmaceuticals
Sep 17, 2025
Maintains: Buy
Price Target: $453 → $520
Current: $446.40
Upside: +16.49%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $82.70
Upside: +25.76%
Ascendis Pharma
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $191.99
Upside: +19.80%
argenx SE
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $712.03
Upside: +24.57%
Sarepta Therapeutics
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $18.36
Upside: -12.85%
PTC Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $58.99
Upside: +28.84%
ACADIA Pharmaceuticals
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $21.05
Upside: +28.27%
BioNTech SE
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $98.08
Upside: +36.62%
Apellis Pharmaceuticals
Jul 16, 2025
Maintains: Neutral
Price Target: $23 → $24
Current: $22.39
Upside: +7.19%
Taysha Gene Therapies
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $3.25
Upside: +146.15%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $99.16
Upside: -4.20%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $7.63
Upside: +96.59%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.41
Upside: -57.49%
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.89
Upside: -9.77%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $13.95
Upside: +93.55%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $8.27
Upside: +238.57%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $68.89
Upside: +1.61%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $8.39
Upside: +376.76%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $142.00
Upside: +26.06%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $12.40
Upside: +77.42%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $5.07
Upside: -40.83%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $8.24
Upside: +82.04%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $8.84
Upside: -77.38%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $29.08
Upside: +161.35%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.37
Upside: +196.74%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.00
Upside: +500.00%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $12.53
Upside: +19.71%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $24.17
Upside: -54.48%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.65
Upside: -45.21%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $1.50
Upside: +300.00%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $11.56
Upside: +29.76%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $52.02
Upside: +15.34%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $2.14
Upside: +647.66%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $14.70
Upside: +192.52%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $202.96
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $9.16
Upside: +3,175.11%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $1.89
Upside: +376.19%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $25.24
Upside: +90.17%